Prasugrel 5 mg in the Very Elderly Attenuates Platelet Inhibition But Maintains Noninferiority to Prasugrel 10 mg in Nonelderly PatientsDavid Erlinge, Dominick J. Angiolillo, Paul A. Gurbel et al.|Journal of the American College of Cardiology|2013Cited by 94
Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight PatientsDavid Erlinge, Kenneth J. Winters, Joseph A. Jakubowski et al.|Journal of the American College of Cardiology|2012Cited by 83
Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patientsHenrik Wagner, David Erlinge, Dominick J. Angiolillo et al.|Journal of Thrombosis and Thrombolysis|2013Cited by 30
The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: A retrospective analysis of the FEATHER studyJoseph A. Jakubowski, David Erlinge, Dominick J. Angiolillo et al.|Thrombosis Research|2014Cited by 24
Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery diseaseStefan James, David Erlinge, Suman Duvvuru et al.|Thrombosis and Haemostasis|2014Cited by 21